Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines…

Toronto, Ontario–(Newsfile Corp. – November 2, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies)…

This Further Defines Development Pathways For Next Generation Of Psychedelic Medicines To Treat Addiction. TORONTO, CANADA, October 28, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology…

TORONTO, CANADA, 22 OCTOBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief…

The clinic will begin delivering ketamine-assisted psychotherapy treatments in October. TORONTO, CANADA, 20 October 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…

Transaction concludes with the launch of “Awakn Clinics Oslo AS” as part of Awakn Life Sciences Nordic Expansion  TORONTO, October 05, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”),…

This was the world’s first published study assessing MDMA-assisted psychotherapy as a treatment for addiction TORONTO, September 23, 2021 – Awakn Life Sciences Corp. (Awakn), (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) a…

Launches Nordics Regional Expansion Dr. Lowan Stewart, One of Europe’s Preeminent Ketamine Physicians, Appointed as Awakn’s Regional Director for the Nordics TORONTO, September ##, 2021 – Awakn Life Sciences Corp. (“Awakn”…

TORONTO, CANADA, 15 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…

TORONTO, CANADA, 02 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that…

Recruitment Has Commenced for the First-Of-Its-Kind, U.K. – based Study, Led by Renowned Ketamine Researcher Toronto, Ontario–(Newsfile Corp. – August 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…

Toronto, Ontario–(Newsfile Corp. – August 12, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…